Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage
In 12 of 93 hypercalcemic patients with metastatic advanced breast cancer treated with tamoxifen the most common life-threatening metabolic complication of flare hypercalcemia developed. All the hypercalcemic patients had osteolytic or mixed lytic and blastic bone metastases. In patients with advanced breast cancer, hypercalcemia develops within the first few weeks of initiation of tamoxifen therapy. In our study group, calcium levels were measured frequently in both serum and urine samples by a semi-autoanalyzer and an autoanalyzer, using standard methods. Elevation of calcium levels was noticed in the tamoxifen-receiving hypercalcemic breast cancer patients, and levels returned to normal when tamoxifen was withdrawn. The median duration of flare hypercalcemia was 9 days (range, 4–16 days). The median calcium value was 13.6 mg/dl (range, 11.7–15.8). The diagnosis of tamoxifen flare hypercalcemia was based on the normal pretreatment serum or urine calcium values and the occurrence of hypercalcemia within the first few weeks of tamoxifen initiation. There are no specific treatment recommendations for hormone flare hypercalcemia, except for tamoxifen withdrawal, which is usually temporary, and the introduction of a low dose of an antihypercalcemic drug. We evaluated the effect of such a drug, gallium nitrate, on flare hypercalcemia. All the patients were treated with hydration, and 6 patients, whose calcium level was above 13.6 mg/dl, were treated with a moderate dose of gallium nitrate (200 mg/m2 per kg) for 5 consecutive days, they achieved normocalcemia and continued with tamoxifen. The median time from hormonal drug initiation to flare hypercalcemia was 17.5 days, and median duration was 9 days. The above result indicates that the serious metabolic complication of hypercalcemia develops due to the iatrogenic effect of tamoxifen, but it can be controlled with an antihypercalcemic drug, gallium nitrate, while continuing tamoxifen therapy. It seems that the use of gallium nitrate in the treatment of flare hypercalcemia could allow safe readministration of tamoxifen and prevent premature tamoxifen discontinuance or withdrawal.
Key wordsbone metastases breast cancer hypercalcemia gallium nitrate flare parathyroid hormone – related protein tamoxifen
Unable to display preview. Download preview PDF.
- 3.Plotkin, D, Lechner, JJ, Jung, WE, Rosen, PJ 1978Tamoxifen flare in advanced breast cancerJAMA826442646Google Scholar
- 4.Sztern, M, Barkan, A, Rakowsky, E, Shainkin-Kestenbaum, R, Marilus, R, Blum, I 1981Hypercalcemia in carcinoma of the breast without evidence of bone destruction: beneficial effect of hormonal therapyCancer123832385Google Scholar
- 6.Kimmick, G, Muss, HB 1995Current status of endocrine therapy for metastatic breast cancerOncology (Huntingt)9877886889–890; discussion 892–894Google Scholar
- 11.Veldhuis, JD, Santen, RJ 1979Tamoxifen flareJAMA825062507Google Scholar
- 13.Ralston, SH, Gallacher, SJ, Patel, U, Campbell, J, Boyle, IT 1990Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patientsAnn Intern Med1499504Google Scholar
- 14.Coleman, RE 1997Skeletal complications of malignancyCancer1515881594Google Scholar
- 17.Tormey, DC, Simon, RM, Lippman, ME, Bull, JM, Myers, CE 1976Evaluation of tamoxifen dose in advanced breast cancer: a progress reportCancer Treat Rep Oct6014511459Google Scholar
- 18.Nikolic-Temasevic, Z, Jelic, S, Popov, I, Radosavljevic, D, Mitrovic, L 2001Tumor “flare” hypercalcemia – an additional indication for bisphosphonates?Oncology60123126Google Scholar
- 19.Legha SS, Powell K, Buzdar AU, Blumenschein GR (1981) Tamoxifen-induced hypercalcemia in breast cancer. 47:2803–2806Google Scholar
- 20.Burtis, WJ, Brady, TG, Orloff, JJ, Ersbak, JB, Warrell, RP,Jr, Olson, BR, Wu, TL, Mitnick, ME, Broadus, AE, Stewart, AF 1990Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancerN Engl J Med1911061112Google Scholar
- 26.Niesvizky, R, Choy, CG, Siegel, D 2002Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrateLeuk Lymphoma43603605Google Scholar
- 27.Berheault-Cvitkovic F, Armand J-P, Tubuana-Hulin M (1996) Randomized, double blind comparison of pamidronate vs gallium nitrate for acute control of cancer-related hypercalcemia. Presented at the 9 EORTC/NC1 symposium, Amsterdam, March 1996Google Scholar